$3.14
-0.08-2.48%
In chiusura: Nov 20, 4:00 PM EST
$2.88
-0.26-8.36%
Post-mercato: Nov 20, 5:47 PM EST

The average analyst price target for Larimar Therapeutics is $15.23, 429.3% above the current price. Of 11 analysts, 11 rate it Buy. Targets range from $5 to $26. The latest change came on Nov 17, 2026, when Wedbush lowered its price target on Larimar Therapeutics from $11 to $9 and kept an Outperform rating.
Price Target Range — 12 Quarters
Analyst Consensus — 11 Analysts
Rating Trend — Last 9 Months